Neoplasia/BPH

	A Nationwide Descriptive Analysis of Real-World Outcomes After Radical Prostatectomy in Japan Using the National Clinical Database. Int J Urol Sakamoto S, Yamamoto K, Yamamoto H, Hatakeyama S, Mizuno R, Yasui T, Kamoto T, Kikuchi E, Ito A, Kume H. PMID: 42466819 [PubMed - indexed for MEDLINE]
	Machine Learning Classification of Prostate Cancer Genomic Sequences Using K-Mer and Sequence-Derived Features. Comput Mol Biosci Rawat K, Banerjee HN, Noble J, Deloatch SN, Banerjee S, Shetty S, Banerjee S. PMID: 42466157 [PubMed]
	Correction to an immunometabolism-related signature for renal clear cell carcinoma diagnosis and therapeutic target. J Cell Commun Signal PMID: 42465982 [PubMed]
	Tumor heterogeneity on contrast-enhanced computed tomography outperforms attenuation ratio in differentiating renal cell carcinoma subtypes: a pathologic correlation study. Pan Afr Med J Araminta ADE, Atmaja MHS, Ferriastuti W. PMID: 42465830 [PubMed - in process]
	The diagnostic value of biparametric magnetic resonance imaging vesical imaging-reporting and data system combined with tumor contact length for assessing muscle invasion in bladder cancer lesions scored vesical imaging-reporting and data system 3: A single-center retrospective analysis. Indian J Urol Bao W, Liu Y, Yang J, Ma X. PMID: 42465796 [PubMed]
	The immunotherapy paradox in high-risk non-muscle-invasive bladder cancer: A tale of three trials. Indian J Urol Agrawal S, Pal AK, Sharma S, Tanwar R, Sharma G. PMID: 42465794 [PubMed]
	The Evidence-Practice Gap in Testosterone Therapy for Prostate Cancer: A Narrative Review. Cureus Aly M, Joseph A, Amer T. PMID: 42465160 [PubMed]
	Prostate Cancer Screening: Current Controversies and Future Directions. Cureus Buali HF, Al Shaibani A, Farouqi US, Abushloa T, Bastawisy A, Aljeeran N, Albenjasim K, Rafie M. PMID: 42465149 [PubMed]
	Post-Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma. Int J Urol Kanayama HO, Kuroda S, Osaka T, Eto M. PMID: 42464667 [PubMed - indexed for MEDLINE]
	Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review). Int J Oncol Baxevanis CN, Stokidis S, Fortis SP, Goulielmaki M, Tsitsilonis OE, Gritzapis AD. PMID: 42464652 [PubMed - indexed for MEDLINE]
	Cost-effectiveness of ferumoxtran-enhanced macrophage-specific-MRI and PSMA-PET/CT versus ePLND for nodal staging in primary prostate cancer: a decision analysis based on updated phase-3 trial data. J Med Econ Zamecnik P, Feuerstein J, Berghahn M, Barentsz J. PMID: 42464573 [PubMed - indexed for MEDLINE]
	Re: Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings in Multiparametric MRI (PRIMARY2): A Multicentre, Non-inferiority, Phase 3, Randomised Controlled Trial. Eur Urol Urso L, Giannarini G, Girometti R, Crestani A, Bauckneht M. PMID: 42463362 [PubMed - as supplied by publisher]
	Abiraterone or Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer: A Nationwide Veterans Affairs Study. JCO Clin Cancer Inform La J, Wang L, Corrigan JK, Lang D, Do NV, Brophy MT, Fillmore NR, Paller CJ. PMID: 42462188 [PubMed - in process]
	Bladder Cancer Management in Brazil's Supplementary Health System: Real-World Practice Patterns. Int Braz J Urol Astua IF, Suartz CV, Chade DC, Soares DFG, Modesto de Souza A Neto, Fernandes RC, Korkes F. PMID: 42462152 [PubMed - indexed for MEDLINE]
	Robot-assisted Partial Nephrectomy with the new HugoRAS System: single center matched-pair analysis. Int Braz J Urol Gonçalves GG, Vinagre N, Magalhães M, Fraga A, Silva-Ramos M. PMID: 42462151 [PubMed - indexed for MEDLINE]
	Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026). Part II: Evaluation and Management of Metastatic Castration-Resistant Prostate Cancer. J Urol Scarpato KR, Cookson MS, Dreicer R, Sayan M, Yu A, D'Anci KE, Pak LJ, Kirkby E. PMID: 42462145 [PubMed - as supplied by publisher]
	Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer. J Urol Scarpato KR, Cookson MS, Dreicer R, Sayan M, Yu A, D'Anci KE, Pak LJ, Kirkby E. PMID: 42462144 [PubMed - as supplied by publisher]
	Imaging of Complications after Prostate Interventions. Radiographics Thompson CP, Takahashi H, Broski SM, Froemming AT, Takahashi N, Woodrum DA, Andrews JR, Kawashima A. PMID: 42461755 [PubMed - indexed for MEDLINE]
	Sex differences in the prognostic value of body mass index after curative nephrectomy for high-risk renal cell carcinoma: a multicenter cohort study. Int J Clin Oncol Koterazawa S, Sumiyoshi T, Shibasaki N, Yamasaki T, Ito N, Segawa T, Inoue K, Kanamaru S, Yoshida T, Okubo K, Sugino Y, Kanno T, Masuda N, Ueda M, Koike S, Hoshiyama A, Araki H, Maekawa K, Takuma T, Yamane T, Kita Y, Goto T, Kobayashi T, Masui K, Daimonji Clinical Application Database Group. PMID: 42461516 [PubMed - as supplied by publisher]
	The training paradox in oncosexuality: a multinational survey on clinician attitudes, barriers, and sexual health communication in geriatric prostate cancer care. World J Urol Loganadane G, Motta M, Lester-Coll NH, Lock M, Colin G, Caravatta L, Debbi K, Lara PC, Espíndola Sandoval M, Basu T, Sangalli C, Goyal S, Abd Elbadee OM, Pasinetti N, Vinh-Hung V, Luigi Banna G, Panades M, D'Andrea M, Osti MF, Nguyen NP. PMID: 42461282 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 189835

Page 1 of 9492



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy